A review of phase II and III drugs for the treatment and management of endometriosis

References

• Morotti M, Remorgida V, Venturini PL, et al. Endometriosis in menopause: a single institution experience. Arch Gynecol Obstetrics. 2012;286(6):1571–1575. doi: 10.1007/s00404-012-2473-5
   PubMed Web of Science ®Google Scholar
• Moradi Y, Shams-Beyranvand M, Khateri S, et al. A systematic review on the prevalence of endometriosis in women. Indian J Med Res. 2021;154(3):446–454. doi: 10.4103/ijmr.IJMR_817_18
   PubMed Web of Science ®Google Scholar
• Vercellini P, Viganò P, Somigliana E, et al. Endometriosis: Pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–275. doi: 10.1038/nrendo.2013.255
   PubMed Web of Science ®Google Scholar
• La Rosa VL, De Franciscis P, Barra F, et al. Quality of life in women with endometriosis: a narrative overview. Minerva Med. 2020 Feb;111(1):68–78. doi: 10.23736/S0026-4806.19.06298-0
   PubMed Web of Science ®Google Scholar
• Vercellini P, Bandini V, Vigano P, et al. Proposal for targeted, neo-evolutionary-oriented, secondary prevention of early-onset endometriosis and adenomyosis. Part I: pathogenic aspects. Hum Reprod. 2023 Nov 10. doi: 10.1093/humrep/dead229
   Web of Science ®Google Scholar
• Roberti Maggiore U L, Ferrero S, Candiani M, et al. Bladder endometriosis: a systematic review of pathogenesis, diagnosis, treatment, impact on fertility, and risk of malignant transformation [figure presented]. Eur Urol. 2017;71(5):790–807. doi: 10.1016/j.eururo.2016.12.015
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Biscaldi E, et al. Ureteral endometriosis: a systematic review of epidemiology, pathogenesis, diagnosis, treatment, risk of malignant transformation and fertility. Human Reproduction Update. 2018;24(6):710–730. doi: 10.1093/humupd/dmy027
   PubMed Web of Science ®Google Scholar
• Remorgida V, Ferrero S, Fulcheri E, et al. Bowel endometriosis: Presentation, diagnosis, and treatment. Obstet Gynecol Surv. 2007;62(7):461–470. doi: 10.1097/01.ogx.0000268688.55653.5c
   PubMed Web of Science ®Google Scholar
• Ceccaroni M, Clarizia R, Roviglione G. Nerve-sparing surgery for deep infiltrating endometriosis: laparoscopic eradication of deep infiltrating endometriosis with Rectal and parametrial resection according to the negrar method. J Minimally Invasive Gynecol. 2020;27(2):263–264. doi: 10.1016/j.jmig.2019.09.002
   PubMed Web of Science ®Google Scholar
• Jacobson TZ, Barlow DH, Garry R, et al. Laparoscopic surgery for pelvic pain associated with endometriosis. Cochrane Database Syst Rev (Online). 2001;4.
   PubMedGoogle Scholar
• Falcone T, Shakiba K, Bena JF, et al. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet & Gynecol. 2008;111(6):1285–1292. doi: 10.1097/AOG.0b013e3181758ec6
   PubMed Web of Science ®Google Scholar
• Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments [review]. Expert Opin Biol Ther. 2019;19(4):343–360. doi: 10.1080/14712598.2019.1581761
   PubMed Web of Science ®Google Scholar
• Vercellini P, Crosignani PG, Abbiati A, et al. The effect of surgery for symptomatic endometriosis: the other side of the story. Human Reproduction Update. 2009;15(2):177–188. doi: 10.1093/humupd/dmn062
   PubMed Web of Science ®Google Scholar
• Vercellini P, Bandini V, Vigano P, et al. Proposal for targeted, neo-evolutionary-oriented secondary prevention of early-onset endometriosis and adenomyosis. Part II: medical interventions. Hum Reprod. 2023 Nov 10. doi: 10.1093/humrep/dead206
   Web of Science ®Google Scholar
• Koga K, Takamura M, Fujii T, et al. Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril. 2015 Oct;104(4):793–801.
   PubMed Web of Science ®Google Scholar
• Koga K, Takamura M, Fujii T, et al. Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Sterility. 2015;104(4):793–801. doi: 10.1016/j.fertnstert.2015.08.026
   PubMed Web of Science ®Google Scholar
• Vercellini P, Somigliana E, Viganò P, et al. Endometriosis: Current therapies and new pharmacological developments. Drugs. 2009;69(6):649–675. doi: 10.2165/00003495-200969060-00002
   PubMed Web of Science ®Google Scholar
• Capras RD, Urda-Cimpean AE, Bolboaca SD. Is scientific medical literature related to endometriosis treatment evidence-based? A systematic review on Methodological quality of randomized clinical trials. Medicina (Kaunas). 2019 Jul 15;55(7):372. doi: 10.3390/medicina55070372
   PubMed Web of Science ®Google Scholar
• Allen C, Hopewell S, Prentice A. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev (Online). 2005;4.
   Web of Science ®Google Scholar
• Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017 Jan 23;1(1):CD004753. doi: 10.1002/14651858.CD004753.pub4
   PubMedGoogle Scholar
• Menakaya U, Infante F, Condous G. Consensus on current management of endometriosis. Hum Reprod. 2013;28(11):3162–3163. doi: 10.1093/humrep/det346
   PubMed Web of Science ®Google Scholar
• DiVasta AD, Feldman HA, Sadler Gallagher J, et al. Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial. Obstet Gynecol. 2015 Sep;126(3):617–627.
   PubMed Web of Science ®Google Scholar
• Teal S, Edelman A. Contraception selection, effectiveness, and adverse effects: a review. JAMA. 2021 Dec 28;326(24):2507–2518. doi: 10.1001/jama.2021.21392
   PubMed Web of Science ®Google Scholar
• Grandi G, Mueller MD, Papadia A, et al. Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis. J Reprod Immunol. 2016;117:30–38. doi: 10.1016/j.jri.2016.06.004
   PubMed Web of Science ®Google Scholar
• Grandi G, Mueller M, Bersinger N, et al. Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells. Am J Reprod Immunol. 2016;76(4):292–298. doi: 10.1111/aji.12552
   PubMed Web of Science ®Google Scholar
• Hood WE, Bond WL. Enovid therapy for premenstrual tension. Obstet Gynecol. 1959 Aug;14(2):239–41.
   PubMed Web of Science ®Google Scholar
• Grandi G, Facchinetti F, Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? Eur J Contracept Reprod Health Care. 2017;22(4):245–246. doi: 10.1080/13625187.2017.1372571
   PubMed Web of Science ®Google Scholar
• Grandi G, Cagnacci A, Fauvolpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10(1):1–10. (1744-7607 (Electronic)) eng. 0000. doi: 10.1517/17425255.2013.844229
   PubMed Web of Science ®Google Scholar
• Vercellini P, Buggio L, Berlanda N, et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Sterility. 2016;106(7):1552–1571.e2. doi: 10.1016/j.fertnstert.2016.10.022
   PubMed Web of Science ®Google Scholar
• Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Sterility. 2018;110(1):137–152.e1. doi: 10.1016/j.fertnstert.2018.03.012
   PubMed Web of Science ®Google Scholar
• Vercellini P. Are combined hormonal contraceptives the neglected treatment for symptomatic endometriosis? Fertil Sterility. 2018;110(1):61–62. doi: 10.1016/j.fertnstert.2018.03.038
   PubMed Web of Science ®Google Scholar
• Muzii L, Maneschi F, Marana R, et al. Oral estroprogestins after laparoscopic surgery to excise endometriomas: continuous or cyclic administration? Results of a multicenter randomized study. J Minim Invasive Gynecol. 2011;18(2):173–178. doi: 10.1016/j.jmig.2010.11.004
   PubMed Web of Science ®Google Scholar
• Seracchioli R, Mabrouk M, Frascà C, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Sterility. 2010;93(1):52–56. doi: 10.1016/j.fertnstert.2008.09.052
   PubMed Web of Science ®Google Scholar
• Maggiore ULR, Remorgida V, Scala C, et al. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand. 2014;93(3):239–247. doi: 10.1111/aogs.12326
   PubMed Web of Science ®Google Scholar
• Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Sterility. 2010;93(7):2150–2161. doi: 10.1016/j.fertnstert.2009.01.071
   PubMed Web of Science ®Google Scholar
• Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009. doi: 10.1093/hropen/hoac009
   PubMedGoogle Scholar
• Buggio L, Dridi D, Barbara G, et al. Novel pharmacological therapies for the treatment of endometriosis. Expert Rev Clin Pharmacol. 2022 Sep;15(9):1039–1052.
   PubMed Web of Science ®Google Scholar
• Grandi G, Farulla A, Sileo FG, et al. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018;19(7):677–686. doi: 10.1080/14656566.2018.1462337
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Venturini PL, et al. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. Eur J Obstet Gynecol Reprod Biol. 2014;174(1):117–122. doi: 10.1016/j.ejogrb.2013.11.030
   PubMedGoogle Scholar
• Walch K, Unfried G, Huber J, et al. Implanon® versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis - a pilot study. Contraception. 2009;79(1):29–34. doi: 10.1016/j.contraception.2008.07.017
   PubMed Web of Science ®Google Scholar
• Ambacher K, Secter M, Sanders AP. The use of progestin subdermal implants in the management of endometriosis-related pain symptoms and quality of life: a systematic review. Curr Med Res Opin. 2022 Mar;38(3):479–486. doi: 10.1080/03007995.2022.2031144
   PubMed Web of Science ®Google Scholar
• Murji A, Biberoglu K, Leng J, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020 May;36(5):895–907.
   PubMed Web of Science ®Google Scholar
• Bizzarri N, Remorgida V, Leone Roberti Maggiore U, et al. Dienogest in the treatment of endometriosis. Expert Opin Pharmacother. 2014 Sep;15(13):1889–1902. doi: 10.1517/14656566.2014.943734
   PubMed Web of Science ®Google Scholar
• Ferrero S, Barra F, Leone Roberti Maggiore U. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018 Jul;78(10):995–1012. doi: 10.1007/s40265-018-0928-0
   PubMed Web of Science ®Google Scholar
• Long-term re-absorbable subcutaneous implant with controled pre-concentrated pharmacologically active polymer substance release for treating endometriosis . Available from: https://patentscope.wipo.int/search/en/detail.jsf?docId=US339379816&docAn=16985891
   Google Scholar
• Della Corte L, Barra F, Mercorio A, et al. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin Drug Metab Toxicol. 2020 Sep;16(9):759–768.
   PubMed Web of Science ®Google Scholar
• Abu Hashim H. Gonadotrophin-releasing hormone analogues and endometriosis: Current strategies and new insights. Gynecological Endocrinol. 2012;28(4):314–321. doi: 10.3109/09513590.2011.650751
   PubMed Web of Science ®Google Scholar
• Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010 Dec 8;2010(12):CD008475
   PubMedGoogle Scholar
• Fedele L, Bianchi S, Bocciolone L, et al. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fertil Sterility. 1993;59(3):516–521. doi: 10.1016/S0015-0282(16)55792-6
   PubMed Web of Science ®Google Scholar
• Bergqvist A, Bergh T, Hogström L, et al. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Sterility. 1998;69(4):702–708. doi: 10.1016/S0015-0282(98)00019-3
   PubMed Web of Science ®Google Scholar
• Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebo-controlled, double-blind study. Fertil Sterility. 1990;54(3):419–427. doi: 10.1016/S0015-0282(16)53755-8
   PubMed Web of Science ®Google Scholar
• Miller JD. Leuprolide acetate for the treatment of endometriosis. Prog clin biol res. 1990;323:337–341.
   PubMedGoogle Scholar
• Miller JD. Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. Am J Obstet Gynecol. 2000;182(6):1483–1488. doi: 10.1067/mob.2000.106846
   PubMed Web of Science ®Google Scholar
• Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Sterility. 1993;60(1):75–79. doi: 10.1016/S0015-0282(16)56039-7
   PubMed Web of Science ®Google Scholar
• Parazzini F, Di Cintio E, Chatenoud L, et al. Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Eur J Obstet Gynecol Reprod Biol. 2000;88(1):11–14. doi: 10.1016/S0301-2115(99)00131-1
   PubMed Web of Science ®Google Scholar
• Guzick DS, Huang LS, Broadman BA, et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Sterility. 2011;95(5):1568–1573. doi: 10.1016/j.fertnstert.2011.01.027
   PubMed Web of Science ®Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis-a randomized, double-blind, multicenter, controlled trial. Fertil Sterility. 2009;91(3):675–681. doi: 10.1016/j.fertnstert.2007.12.080
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–641. doi: 10.1093/humrep/dep469
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21(1):248–256. doi: 10.1093/humrep/dei290
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Sterility. 2006;85(2):314–325. doi: 10.1016/j.fertnstert.2005.07.1315
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20(7):1993–1998. doi: 10.1093/humrep/deh869
   PubMed Web of Science ®Google Scholar
• Ferreira RA, Vieira CS, Rosa-E-Silva JC, et al. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception. 2010;81(2):117–122. doi: 10.1016/j.contraception.2009.08.003
   PubMed Web of Science ®Google Scholar
• Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Sterility. 2011;95(2):492–496. doi: 10.1016/j.fertnstert.2010.08.042
   PubMed Web of Science ®Google Scholar
• Lemay A, Maheux R, Huot C, et al. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol. 1988;158(2):233–236. doi: 10.1016/0002-9378(88)90128-7
   PubMed Web of Science ®Google Scholar
• Dmowski WP, Radwanska E, Binor Z, et al. Ovarian suppression induced with Buserelin, or danazol in the management of endometriosis: a randomized, comparative study. Fertil Sterility. 1989;51(3):395–400. doi: 10.1016/S0015-0282(16)60543-5
   PubMed Web of Science ®Google Scholar
• Dawood MY, Spellacy WN, Dmowski WP, et al. A comparison of the efficacy and safety of buserelin vs danazol in the treatment of endometriosis. Protocol 310 study group. Prog Clin Biol Res. 1990;323:253–267.
   PubMedGoogle Scholar
• Agarwal SK, Hamrang C, Henzl MR, et al. Nafarelin vs. Leuprolide acetate depot for endometriosis: Changes in bone mineral density and vasomotor symptoms. Obstet Gynaecol Reprod Med. 1997;42(7):413–423.
   Google Scholar
• Minaguchi H, Uemura T, Shirasu K. Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis–multicenter trial in Japan. Prog clin biol res. 1986;225:211–225.
   PubMedGoogle Scholar
• Adamson GD, Kwei L, Edgren RA. Pain of endometriosis: effects of nafarelin and danazol therapy. Int J Fertil Menopausal Stud. 1994;39(4):215–217.
   PubMedGoogle Scholar
• Henzl MR, Corson SL, Moghissi K, et al. Administration of Nasal Nafarelin as compared with oral danazol for endometriosis. N Engl J Med. 1988;318(8):485–489. doi: 10.1056/NEJM198802253180805
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Maganza C, et al. Aromatase and endometriosis: Estrogens play a role. Ann NY Acad Sci2014. 2014;1317(1):17–23. doi: 10.1111/nyas.12411
   PubMedGoogle Scholar
• Ferrero S, Gillott DJ, Venturini PL, et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review [review]. Reprod Biol Endocrinol. 2011;9(1):89. doi: 10.1186/1477-7827-9-89
   PubMedGoogle Scholar
• Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018;19(10):1109–1125. doi: 10.1080/14656566.2018.1494154
   PubMed Web of Science ®Google Scholar
• Zajec V, Mikus M, Vitale SG, et al. Current status and challenges of drug development for hormonal treatment of endometriosis: a systematic review of randomized control trials. Gynecol Endocrinol. 2022 Sep;38(9):713–720.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Biscaldi E, Luigi Venturini P, et al. Aromatase inhibitors in the treatment of bladder endometriosis. Gynecological Endocrinol. 2011;27(5):337–340. doi: 10.3109/09513590.2010.500425
   PubMed Web of Science ®Google Scholar
• Remorgida V, Abbamonte LH, Ragni N, et al. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust NZ J Obstetrics Gynaecol. 2007;47(3):222–225. doi: 10.1111/j.1479-828X.2007.00722.x
   PubMed Web of Science ®Google Scholar
• Remorgida V, Abbamonte HL, Ragni N, et al. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Sterility. 2007;88(3):724–726. doi: 10.1016/j.fertnstert.2006.12.027
   PubMed Web of Science ®Google Scholar
• Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009;24(12):3033–3041. doi: 10.1093/humrep/dep302
   PubMed Web of Science ®Google Scholar
• Ferrero S, Camerini G, Ragni N, et al. Letrozole and norethisterone acetate in colorectal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010;150(2):199–202. doi: 10.1016/j.ejogrb.2010.02.023
   PubMed Web of Science ®Google Scholar
• Ferrero S, Venturini PL, Gillott DJ, et al. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reprod Biol Endocrinol. 2011;9(1):88. doi: 10.1186/1477-7827-9-88
   PubMedGoogle Scholar
• Ferrero S, Remorgida V, Venturini PL. Current pharmacotherapy for endometriosis. Expert Opin Pharmacother. 2010;11(7):1123–1134. doi: 10.1517/14656561003685880
   PubMed Web of Science ®Google Scholar
• Ferrero S, Leone Roberti Maggiore U, Scala C, et al. Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies. Arch Gynecol Obstet. 2013 Mar;287(3):447–453.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Luan X, Wang Y. Letrozole combined with oral contraceptives versus oral contraceptives alone in the treatment of endometriosis-related pain symptoms: a pilot study. Gynecol Endocrinol. 2021 Jan;37(1):51–55. doi: 10.1080/09513590.2020.1807502
   PubMed Web of Science ®Google Scholar
• Lall Seal S, Kamilya G, Mukherji J, et al. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review. Fertil Steril. 2011 Jan;95(1):291 e15–8.
   PubMed Web of Science ®Google Scholar
• Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004 Jan;19(1):160–167.
   PubMed Web of Science ®Google Scholar
• Alborzi S, Hamedi B, Omidvar A, et al. A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet. 2011 Jul;284(1):105–110.
   PubMed Web of Science ®Google Scholar
• Hefler LA, Grimm C, van Trotsenburg M, et al. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril. 2005 Oct;84(4):1033–1036.
   PubMed Web of Science ®Google Scholar
• Acien P, Velasco I, Acien M. Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial. BMC Womens Health. 2021 May 20;21(1):211. doi: 10.1186/s12905-021-01347-9
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Mais V, et al. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs. 2018 May;27(5):445–458.
   PubMed Web of Science ®Google Scholar
• Clemenza S, Sorbi F, Noci I, et al. From pathogenesis to clinical practice: emerging medical treatments for endometriosis. Best practice and research: clinical Obstetrics and gynaecology. Best Pract Res Clin Obstet Gynaecol. 2018;51:92–101.
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Endometriosis and medical therapy: from progestogens to progesterone resistance to GNRH antagonists: a review. J Clin Med. 2021;10(5):1–21. doi: 10.3390/jcm10051085
   Web of Science ®Google Scholar
• Donnez J, Taylor RN, Taylor HS. Partial suppression of estradiol: a new strategy in endometriosis management? Fertil Sterility. 2017;107(3):568–570. doi: 10.1016/j.fertnstert.2017.01.013
   PubMed Web of Science ®Google Scholar
• Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992;166(2):740–745. doi: 10.1016/0002-9378(92)91706-G
   PubMed Web of Science ®Google Scholar
• Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40. doi: 10.1056/NEJMoa1700089
   PubMed Web of Science ®Google Scholar
• Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis results from two extension studies. Obstet & Gynecol. 2018;132(1):147–160. doi: 10.1097/AOG.0000000000002675
   PubMed Web of Science ®Google Scholar
• D’Hooghe T, Fukaya T, Osuga Y, et al. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study. Hum Reprod. 2019;34(5):813–823. doi: 10.1093/humrep/dez028
   PubMed Web of Science ®Google Scholar
• Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertil Sterility. 2020;114(1):44–55. doi: 10.1016/j.fertnstert.2020.02.114
   PubMed Web of Science ®Google Scholar
• Osuga Y, Seki Y, Tanimoto M, et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study. Fertil Sterility. 2021;115(2):397–405. doi: 10.1016/j.fertnstert.2020.07.055
   PubMed Web of Science ®Google Scholar
• Osuga Y, Seki Y, Tanimoto M, et al. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results. BMC Women’s Health. 2021;21(1). doi: 10.1186/s12905-021-01393-3
   Web of Science ®Google Scholar
• Harada T, Osuga Y, Suzuki Y, et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. Fertil Sterility. 2022;117(3):583–592. doi: 10.1016/j.fertnstert.2021.11.013
   PubMed Web of Science ®Google Scholar
• Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet. 2022;399(10343):2267–2279. doi: 10.1016/S0140-6736(22)00622-5
   PubMed Web of Science ®Google Scholar
• Lamb YN. Elagolix: First Global Approval. Drugs. 2018;78(14):1501–1508. doi: 10.1007/s40265-018-0977-4
   PubMed Web of Science ®Google Scholar
• Carr B, Giudice L, Dmowski WP, et al. Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study. J Endometr Pelvic Pain Disord. 2013 Jul;5(3):105–115.
   PubMedGoogle Scholar
• Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reproductive Sciences. 2014;21(11):1341–1351. doi: 10.1177/1933719114549848
   PubMed Web of Science ®Google Scholar
• Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014 Mar;21(3):363–371.
   PubMed Web of Science ®Google Scholar
• OBC ÁN, Jiang P, Jiang P. Treatment of endometriosis associated pain with elagolix, an oral GnRH antagonist results from a phase 2 randomized controlled study. J Endometriosis. 2015;7(2):56–62. doi: 10.5301/je.5000211
   Google Scholar
• Vercellini P, Viganò P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold. Hum Reprod. 2019;34(2):193–199. doi: 10.1093/humrep/dey368
   PubMed Web of Science ®Google Scholar
• Leyland N, Estes SJ, Lessey BA, et al. A Clinician’s Guide to the treatment of endometriosis with Elagolix. J Womens Health (Larchmt). 2021 Apr;30(4):569–578.
   PubMed Web of Science ®Google Scholar
• Simon JMD, Kim JHMD, Thomas JMD. Long-term safety of elagolix with hormonal add-back therapy in women with endometriosis-associated pain: 24-month results [A86]. Obstet & Gynecol. 2022;139(1):25S–26S. doi: 10.1097/01.AOG.0000826672.69977.4c
   Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337(23):1641–1647. doi: 10.1056/NEJM199712043372301
   PubMed Web of Science ®Google Scholar
• Simsa P, Mihalyi A, Kyama CM, et al. Selective estrogen-receptor modulators and aromatase inhibitors: promising new medical therapies for endometriosis? Women’s Health. 2007;3(5):617–628. doi: 10.2217/17455057.3.5.617
   PubMedGoogle Scholar
• Yao Z, Shen X, Capodanno I, et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Invest Surg. 2005;18(4):177–183. doi: 10.1080/08941930591004412
   PubMed Web of Science ®Google Scholar
• Altintas D, Kokcu A, Kandemir B, et al. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010;150(1):84–87. doi: 10.1016/j.ejogrb.2010.02.004
   PubMed Web of Science ®Google Scholar
• Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet & Gynecol. 2008;111(1):88–96. doi: 10.1097/01.AOG.0000297307.35024.b5
   PubMed Web of Science ®Google Scholar
• Alvarez P, Bogen O, Levine JD. Role of nociceptor estrogen receptor GPR30 in a rat model of endometriosis pain. Pain. 2014 Dec;155(12):2680–2686. doi: 10.1016/j.pain.2014.09.035
   PubMed Web of Science ®Google Scholar
• Kulak JJ, Fischer C, Komm B, et al. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology. 2011;152(8):3226–3232. doi: 10.1210/en.2010-1010
   PubMed Web of Science ®Google Scholar
• Sakr S, Naqvi H, Komm B, et al. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment. Endocrinology. 2014 Apr;155(4):1489–1497.
   PubMed Web of Science ®Google Scholar
• Flores VA, Stachenfeld NS, Taylor HS. Bazedoxifene-Conjugated Estrogens for Treating Endometriosis. Obstet & Gynecol. 2018;132(2):475–477. doi: 10.1097/AOG.0000000000002739
   PubMed Web of Science ®Google Scholar
• Hill AM, Lessey B, Flores VA, et al. Bazedoxifene/Conjugated estrogens in combination with leuprolide for the treatment of endometriosis. Clin Case Rep. 2018 Jun;6(6):990–994.
   PubMed Web of Science ®Google Scholar
• Vannuccini S, Clemenza S, Rossi M, et al. Hormonal treatments for endometriosis: the endocrine background. Rev Endocr Metab Disord. 2022;23(3):333–355. doi: 10.1007/s11154-021-09666-w
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Wada O, Takada I, et al. Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand. Biochem Biophys Res Commun. 2003 Dec 19;312(3):656–662. doi: 10.1016/j.bbrc.2003.10.178
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Shibata J, Yonekura K, et al. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res. 2005 Jan 1;11(1):315–322. doi: 10.1158/1078-0432.315.11.1
   PubMed Web of Science ®Google Scholar
• Harada T, Ohta I, Endo Y, et al. SR-16234, a novel selective estrogen receptor modulator for pain symptoms with endometriosis: an open-label clinical trial. Yonago Acta Med. 2017;60(4):227–233. doi: 10.33160/yam.2017.12.003
   PubMed Web of Science ®Google Scholar
• Singh SS, Belland L, Leyland N, et al. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids. Am J Obstet Gynecol. 2018;218(6):563–572.e1. doi: 10.1016/j.ajog.2017.12.206
   PubMed Web of Science ®Google Scholar
• Oskari H, Kimmo K, Horacio C, et al. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem. 1987;26(2):279–284. doi: 10.1016/0022-4731(87)90083-5
   PubMedGoogle Scholar
• Islam MS, Afrin S, Jones SI, et al. Selective Progesterone Receptor Modulators - Mechanisms and Therapeutic Utility. Endocrine Reviews. 2020;41(5). doi: 10.1210/endrev/bnaa012
   PubMed Web of Science ®Google Scholar
• Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):107–116. doi: 10.1080/17425255.2018.1417389
   PubMed Web of Science ®Google Scholar
• Gatti M, Poluzzi E, De Ponti F, et al. Liver injury with ulipristal acetate: exploring the underlying pharmacological basis. Drug Saf. 2020;43(12):1277–1285. doi: 10.1007/s40264-020-00975-8
   PubMed Web of Science ®Google Scholar
• Middelkoop MA, de Lange ME, Clark TJ, et al. Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids. Hum Reprod. 2022 May 3;37(5):884–894. doi: 10.1093/humrep/deac009
   PubMed Web of Science ®Google Scholar
• De Milliano I, Van Hattum D, Ket JCF, et al. Endometrial changes during ulipristal acetate use: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2017;214:56–64. doi: 10.1016/j.ejogrb.2017.04.042
   PubMed Web of Science ®Google Scholar
• Evangelisti G, Barra F, Perrone U, et al. Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids. Expert Opin Drug Metab Toxicol. 2022 Jul;18(7–8):441–457. doi: 10.1080/17425255.2022.2113381
   PubMed Web of Science ®Google Scholar
• Barra F, Romano A, Grandi G, et al. Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis. Expert Opin Investig Drugs. 2019 Jun;28(6):501–504.
   PubMed Web of Science ®Google Scholar
• Pohl O, Bestel E, Gotteland JP. Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256–1265. doi: 10.1177/1933719114522526
   PubMed Web of Science ®Google Scholar
• Purohit A, Fusi L, Brosens J, et al. Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. Hum Reprod. 2008 Feb;23(2):290–297.
   PubMed Web of Science ®Google Scholar
• Day JM, Tutill HJ, Purohit A, et al. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer. 2008 Sep;15(3):665–692.
   PubMed Web of Science ®Google Scholar
• Delvoux B, D’Hooghe T, Kyama C, et al. Inhibition of type 1 17 beta-hydroxysteroid dehydrogenase impairs the synthesis of 17beta-estradiol in endometriosis lesions. J Clin Endocrinol Metab. 2014 Jan;99(1):276–284.
   PubMed Web of Science ®Google Scholar
• National Institute for H, Care E. Endometriosis: diagnosis and management. NICE guideline NG73. Endometriosis: Diagnosis Management. 2017
   Google Scholar
• Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opin Drug Metab Toxicol. 2018;14(4):399–415. doi: 10.1080/17425255.2018.1461840
   PubMed Web of Science ®Google Scholar
• Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017 Mar;107(3):533–536. doi: 10.1016/j.fertnstert.2017.01.003
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011 Oct 25;343(oct25 4):d6423. doi: 10.1136/bmj.d6423
   PubMedGoogle Scholar
• Di Meglio G, Crowther C, Simms J. Contraceptive care for Canadian youth. Paediatr Child Health. 2018 Jul;23(4):271–277. doi: 10.1093/pch/pxx192
   PubMed Web of Science ®Google Scholar
• Powell A. Choosing the right oral contraceptive pill for teens. Pediatr Clin North Am. 2017 Apr;64(2):343–358. doi: 10.1016/j.pcl.2016.11.005
   PubMed Web of Science ®Google Scholar
• Manzoli L, De Vito C, Marzuillo C, et al. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf. 2012 Mar 1;35(3):191–205. doi: 10.2165/11598050-000000000-00000
   PubMed Web of Science ®Google Scholar
• McKinnon B, Mueller M, Montgomery G. Progesterone resistance in endometriosis: an acquired property? Trends Endocrinol Metab. 2018;29(8):535–548. doi: 10.1016/j.tem.2018.05.006
   PubMed Web of Science ®Google Scholar
• Barra F, Ferrero S. Adhesion proteins: suitable therapeutic targets or biomarkers of therapy response for endometriosis? Acta Obstet Gynecol Scand. 2019;98(6):810–811. doi: 10.1111/aogs.13533
   PubMed Web of Science ®Google Scholar
• Dababou S, Garzon S, Lagana AS, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021 Jul 18;30(9):903–911. doi: 10.1080/13543784.2021.1957830
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019 Apr;55(4):237–246. doi: 10.1358/dot.2019.55.4.2930713
   PubMed Web of Science ®Google Scholar
• Vercellini P, Vigano P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold. Hum Reprod. 2019 Feb 1;34(2):193–199. doi: 10.1093/humrep/dey368
   PubMed Web of Science ®Google Scholar
• Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019 Apr;19(4):343–360. doi: 10.1080/14712598.2019.1581761
   PubMed Web of Science ®Google Scholar
• Etrusco A, Barra F, Chiantera V, et al. Current medical therapy for adenomyosis: from bench to bedside. Drugs. 2023 Oct 14;83(17):1595–1611. doi: 10.1007/s40265-023-01957-7
   PubMedGoogle Scholar
• Morotti M, Venturini PL, Biscaldi E. et al. Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:4–10.
   PubMed Web of Science ®Google Scholar
• Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K. et al. Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017 Apr;211:108–111.
   PubMed Web of Science ®Google Scholar